2021 TEIN Summer Workshop (7/28)

Value of the Information & Strength of the Argument

The lectures provide valuable insights into the current state of neuroimaging in AD, with a strong emphasis on the transition to biomarker-based diagnosis. The argumentation is solid, supported by references to key studies, FDA approvals, and the NIA-AA framework. The speakers effectively explain the rationale behind the use of amyloid and tau PET, and the discussion on aducanumab highlights the practical implications. However, the presentation is largely a review of existing knowledge rather than presenting new data, and some parts are dense with technical details that may be challenging for non-specialists.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with the speakers citing established literature and regulatory approvals. The sources mentioned include the NIA-AA criteria, the development of PiB by Klunk et al., and FDA-approved tracers. The title accurately reflects the content, which is a workshop on neuroimaging and radiopharmaceuticals. The presentation is well-structured, but the lack of explicit citations in the video itself (no on-screen references) means viewers must rely on the description for sources. The description lists the topics but does not provide direct links to sources, which is a minor limitation.

The title accurately reflects the content, which is a workshop on neuroimaging and radiopharmaceuticals for Alzheimer's disease.

8/10

The lecture is delivered by experts in nuclear medicine and radiochemistry, presenting established and emerging biomarkers (amyloid and tau PET) with reference to key studies and regulatory approvals. The content aligns with current scientific consensus, though it is a lecture and not peer-reviewed.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to the workshop and overview of Alzheimer's disease.
• 10:00Discussion on the historical NINCDS-ADRDA criteria and limitations.
• 20:00Introduction of Pittsburgh compound B (PiB) and its impact.
• 30:00Explanation of amyloid PET imaging and visual assessment.
• 40:00Revision of AD criteria in 2011 and incorporation of biomarkers.
• 50:00Introduction of tau PET and its role in AD.
• 1:00:00Discussion on aducanumab and the controversy surrounding its approval.
• 1:10:00Second lecture: Radiopharmaceuticals for Alzheimer's disease.
• 1:20:00Review of amyloid and tau tracers, including their development and challenges.
• 1:30:00Q&A and discussion session.

• NIA-AA Research Framework — Mentioned as the 2018 framework for biological definition of Alzheimer's disease.
• Pittsburgh compound B (PiB) — Discussed as the first amyloid PET tracer developed by Klunk et al.
• FDA-approved amyloid tracers — Mentioned florbetapir, flutemetamol, and florbetaben as approved agents.
• Tau PET tracers — Mentioned AV-1451 (flortaucipir) as the first FDA-approved tau tracer.
• Aducanumab — Discussed as the first FDA-approved amyloid-targeting therapy, with controversy.

• NIA-AA Research Framework — Supports the biological definition of AD.
• Pittsburgh compound B — Historical development of amyloid PET.
• Tau PET imaging — Review of tau tracers.

• Aducanumab controversy — The approval of aducanumab was controversial due to conflicting trial results and lack of PET requirement in the label.